Treatment for Clostridium-difficile Infection With IMM529

Status Terminated

Clinical Trial Summary

This study will evaluate the safety and tolerability of IMM-529 together with standard of care (SOC) in patients with Clostridium-difficile Infection.

Clinical Trial Description

Subjects who provide voluntary written informed consent will be screened for eligibility. Subjects meeting all of the inclusion and none of the exclusion criteria will be eligible to participate.

Eligible subjects will be randomized up to 3 weeks post diagnosis of Clostridium-difficile Infection given SOC initiated already.

Each subject will return to the study clinic for assessment and required study procedures on Day 7, Day 14, Week 4, Week 8 and Week 12 post randomization. Treatment duration will be 28 days and follow up will last up to 12 weeks post randomization. ;

Study Design

Related Conditions & MeSH terms

Clostridium Difficile Infection
Clostridium Difficile Infection Recurrence
Clostridium Infections
Communicable Diseases
Infection
Recurrence

Clinical Trial Details

NCT number	NCT03065374
Study type	Interventional
Source	Immuron Ltd.
Contact
Status	Terminated
Phase	Phase 1/Phase 2
Start date	September 1, 2017
Completion date	November 7, 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02214771` - Description of the Use of fidAxomicin in Hospitalized Patients With Documented Clostridium diFficile iNfection and of the managEment of These Patients	N/A
Withdrawn	`NCT01552668` - Fidaxomicin to Prevent Clostridium Difficile Colonization	Phase 4
Recruiting	`NCT03325855` - Fecal Microbiota Transplant National Registry
Not yet recruiting	`NCT03586206` - Relationship Between C. Difficile Toxins' Serum Level With C. Difficile Infection
Suspended	`NCT03350711` - A Screening and Recruitment Study in Adults Expressing Interest in the Emory Microbiota Enrichment Program
Withdrawn	`NCT03643887` - Phase II Trial of Fecal Microbiota Transplant (FMT) for VRE and CRE Patients	Phase 2
Terminated	`NCT04000555` - Oral Vancomycin for Secondary Prophylaxis of Clostridium Difficile Infection (CDI)	Phase 4
Completed	`NCT03710694` - Safety and Efficacy of DAV132 in Patients at High-Risk for Clostridium Difficile Infection (CDI)	N/A
Completed	`NCT02865616` - MET-2 Clinical Study for Recurrent Clostridium Difficile Infection (CDI)	Phase 1
Recruiting	`NCT04940468` - High- Fiber/ Low-fat Diet for Prevention of Recurrent Clostridioides Difficile Infection in Oncology	N/A
Completed	`NCT02589847` - Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection	Phase 2
Not yet recruiting	`NCT01942447` - Fecal Microbiota Transplantation in Recurrent or Refractory Clostridium Difficile Colitis	N/A
Active, not recruiting	`NCT02086916` - Novel Biomarkers to Predict Outcome in Clostridium Difficile Infection	N/A
Completed	`NCT01230957` - Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults	Phase 2
Completed	`NCT01241552` - A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)	Phase 3
Not yet recruiting	`NCT04567134` - Clostridioides Difficile Infection - a Prospective Nationwide Epidemiologic Study in Korea
Completed	`NCT04075422` - Bezlotoxumab - in "Real Life" - During the First Episode of Clostridium Difficile Infection in Patients With High Risk of Recurrence.
Recruiting	`NCT03712722` - Fecal Microbiota Transplantation (FMT) for Clostridium Difficile
Recruiting	`NCT05192148` - Seroprevalence of Antibodies to Surface Antigens and Toxins of Clostridioides Difficile	N/A
Completed	`NCT02981316` - Treatment of Recurrent Clostridium Difficile Infection With RBX7455	Phase 1